Radiopharm completes constructive End‑of‑Phase‑2 meeting with FDA for brain‑metastasis imaging agent RAD101
Radiopharm Theranostics held an End‑of‑Phase‑2 meeting with the U.S. Food and Drug Administration to discuss its investigational imaging agent RAD101 for detecting brain metastases. The agency gave a clear regulatory framework and confirmed Fast Track Designation. The company said the 93% concordance with MRI in Phase 2b met the trial’s primary endpoint and is moving forward with Phase 3 readiness activities while evaluating strategic partners. Official meeting minutes are expected within about 30 days.
Why it matters
The FDA feedback provides regulatory clarity that could accelerate RAD101’s path to a pivotal trial and eventual approval, which may expand the market for brain‑metastasis imaging. The company’s statement that it will advance Phase 3 planning and seek partners suggests potential future revenue streams if the program succeeds.
Key facts
- 1Radiopharm completed an End‑of‑Phase‑2 meeting with the FDA regarding RAD101. globenewswire.com
- 2RAD101 showed 93% concordance with MRI across all evaluable lesions in the Phase 2b trial. globenewswire.com
- 3The FDA granted Fast Track Designation to RAD101. globenewswire.com
- 4Radiopharm expects to receive the FDA’s official meeting minutes within approximately 30 days. globenewswire.com
- 5Radiopharm is preparing Phase 3 readiness activities and evaluating strategic partnership opportunities. globenewswire.com
- 6Radiopharm announced a partnership with Siemens Healthineers to manufacture and distribute 18F‑labeled RAD101 for the upcoming U.S. Phase 3 trial. globenewswire.com
Summary written by AlphAI from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.